Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo

European Journal of Haematology

Volumn 65, Issue 6, 2000, Pages 357-369

  Von Känel, Roland ^a   Dimsdale, Joel E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Blood coagulation; Catecholamines; Fibrinolysis; Platelets; Psychological stress; Sympathetic nervous system

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BLOOD CLOTTING FACTOR 8; CATECHOLAMINE; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; BLOOD CLOTTING; DOSE RESPONSE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; IN VIVO STUDY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOSIS;

ADRENERGIC AGONISTS; CATECHOLAMINES; HEMOSTASIS; HUMANS; SYMPATHETIC NERVOUS SYSTEM; THROMBOPHILIA;

EID: 0033665898     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.065006357.x     Document Type: Review

References (157)

1. An experimental study of the sugar content and extra vascular coagulation of the blood after administration of adrenalin
2. Factors affecting the coagulation time of blood. II. The hastening or retarding of coagulation by adrenalin injections
3. Zur kreislaufanaleptischen und telehamostyptischen Wirkung des Nebennierenextraktes
4. Observations on fibrinolysis. Experimental activity produced by exercise or adrenaline
5. Increase in antihemophilic globulin activity following infusion of adrenaline
6. CNS influence on plasma levels of factor 8 activity
7. The contribution of thrombosis to the clinical expression of coronary atherosclerosis
8. The sympathetic nervous system and ischaemic heart disease
9. Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease: High factor V clotting activity is an independent risk factor for myocardial infarction
10. Factor VIII, ABO blood group and the incidence of ischaemic heart disease
11. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
12. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
13. Platelet hyperreactivity and inefficient spontaneous thrombolysis in patients at high risk from an acute coronary event
14. Hemostasis in normotensive and hypertensive men: Results of the PROCAM study. The prospective cardiovascular Munster study
15. Plasma concentration of coagulation and fibrinolysis factors and platelet function in hypertension
16. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation
17. Thromboembolic diseases: Biochemical mechanisms and new possibilities of biological diagnosis
18. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease
19. Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis
20. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
21. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study
22. Plasma and platelet free catecholamine concentrations in patients with familial hypercholesterolaemia
23. Plasma catecholamines and essential hypertension. An analytical review
24. Interrelationships among measures of autonomic activity and cardiovascular risk factors during orthostasis and the oral glucose tolerance test
25. Sympathetic nervous system activity and the heart
26. Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease
27. Sympathetic nerve activity in the spasm-induced coronary artery region is associated with disease activity of vasospastic angina
28. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia
29. The autonomic nervous system and sudden death
30. Intravascular platelet aggregation in the heart induced by norepinephrine
31. What do plasma and urinary measures of catecholamines tell us about human response to stressors?
32. Activation of haemostasis by exercise, mental stress and adrenaline: Effects on platelet sensitivity to thrombin and thrombin generation
33. Epinephrine exerts anticoagulant effects during human endotoxemia
34. Effect of circulating epinephrine on platelet function and hematocrit
35. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during infusion of isoproterenol and phenylepinephrine
36. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression
37. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirine
38. Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers
39. A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training
40. Alpha-adrenoceptor blockade by phentolamine inhibits adrenaline-induced platelet activation in vivo without affecting resting measurements
41. Fibrinolytic response during exercise and epinephrine infusion in the same subjects
42. Significance of platelet beta-adrenoceptors for platelet responses in vivo and in vitro
43. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis
44. Platelet aggregability in humans: Contrasting in vivo and in vitro findings during sympatho-adrenal activation and relationship to serum lipids
45. Changes of plasma coagulation and fibrinolysis in response to mental stress
46. In vivo biosynthesis of thromboxane and prostacyclin during exposure to physiological levels of epinephrine
47. Altered platelet function during mental stress and adrenaline infusion in humans: Evidence for an increased aggregability in vivo as measured by filtragometry
48. Effects of noradrenaline infusion on platelet catecholamine levels and platelet aggregation
49. Increased platelet and vascular smooth muscle reactivity to low-dose adrenaline infusion in mild essential hypertension
50. Desensitization of platelet alpha 2-adrenoceptors after short term infusions of adrenoceptor agonist in man
51. Adrenaline infusion evokes increased thromboxane B2 production by platelets in healthy men: The effect of beta-adrenoceptor blockade
52. Platelet volume, platelet release reaction and platelet response to infused adrenaline are increased in essential hypertension
53. Effects of adrenaline infusion on platelet number, volume and release reaction
54. The potentiating effect of cortisone (prednisolone) on the fibrinolytic and clotting factor VIII responses to intravenous infusion of adrenaline in man
55. Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion
56. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension
57. The fibrinolytic response of man to vasoactive drugs measured in arterial blood
58. In vitro and in vivo effects of adrenaline and phentolamine on platelet function
59. Factor-VIII activity and antigen, platelet count and biochemical changes after adrenoceptor stimulation
60. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs
61. The effect of noradrenalin infusion on plasma and platelet lipids and platelet function in man
62. The effect of propranolol, alprenolol and practolol on the fibrinolytic and factor VIII responses to adrenaline and salbutamol in man
63. Enhancement of plasminogen activator by vasopressin and adrenaline: A role of cyclic AMP?
64. The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline, isoprenaline and salbutamol in man
65. The systemic release of plasminogen activator to intravenous adrenaline in man: Dose response studies
66. Rise of factor VIII after exercise and adrenaline infusion, measured by immunological and biological techniques
67. Effects of adrenaline and alprenolol (aptin®) on blood coagulation and fibrinolysis in man
68. Appearance of thrombogenic tendency induced by adrenaline and its prevention by beta-adrenergic blocking agent, nialamide, and pyridinolcarbamate
69. Adrenergic mechanisms in the systemic plasminogen activator response to adrenaline in man
70. Effects of adrenaline and noradrenaline on euglobulin lysis time and effects of adrenergic receptor blocking agents on shortening of lysis time by adrenaline
71. The rise in factor VIII after administration of adrenaline
72. Fibrinolytic and forearm blood flow responses to intravenous adrenaline in healthy subjects
73. Alterations of fibrinolysis and blood coagulation
74. The effect of epinephrine-induced elevation of plasma-free fatty acids on platelet aggregation in man
75. Relationships between spleen, platelets and factor 8 levels
76. The rise in factor-8 concentration after infusion of adrenaline
77. The effect of adrenergic blockers on the action of adrenaline on the factor-VIII activity in the plasma
78. The fibrinolytic response to moderate exercise and intravenous adrenaline in the same subjects
79. The rise in clotting factor 8 induced in man by adrenaline: Effect of alpha- and betablockers
80. Les rapports entre le systeme nerveux et les phenomenes de coagulation et de fibrinolyse
81. The effect of some physiological stimuli on fibrinolytic activity in man measured by the heparin fractionation method
82. Observations on adrenaline-induced fibrinolysis in man
83. Spontaneous fibrinolysis and the changes produced by adrenaline, fatty meal, storage and diurnal rhythm on fibrinolytic activity
84. Studio degli effetti dell' adrenalina sulla emocoagulazione e sulla fibrinolisi
85. Considerazioni sull' aumento dell' attivita fibrinolitica indotto dalle amine simpatiche
86. Der Einfluss von Adrenalin und Noradrenalin auf die Blutgerinnung
87. Fibrinolysis induced by pressor amines
88. Effect of adrenaline and noradrenaline on 'silicone-like property' of blood vessels
89. Antifibrinolytic activity in primary carcinoma of the liver
90. Studies on enhanced fibrinolytic activity in man
91. The effect of adrenaline infusion on human blood coagulation
92. On the production of plasma fibrinolytic activity within veins
93. Emocoagulazione e ormoni influenza dell' adrenalina sulla prima fase della coagulazione sanguigna
94. Fibrinolysis and the eosinophil count
95. Increased plasma prothrombin activity after epinephrine injections; relation to hyperglycemia
96. Pooling of platelets in the spleen: Role in the pathogenesis of 'hypersplenic' thrombocytopenia
97. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells
98. Intracellular trafficking of factor VIII to von Willebrand factor storage granules
99. An endothelial storage granule for tissue-type plasminogen activator
100. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA
101. Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: Implications for a neurologic control of vessel wall fibrinolysis and rigidity
102. Targeting of tissue plasminogen activator into the regulated secretory pathway of neuroendocrine cells
103. Binding and release of factor VIII/von Willebrand's factor by human endothelial cells
104. Epinephrine induces von Willebrand factor release from cultured endothelial cells: Involvement of cyclic AMP-dependent signalling in exocytosis
105. Regulation of factor VIII expression and activity by von Willebrand factor
106. Perfused rat hindlegs. A model to study plasminogen activator release
107. Tissue-type plasminogen activator release in response to epinephrine in perfused rat hindlegs
108. Pharmacological stimulation of t-PA release
109. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress
110. Regulation of local tissue-tye plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature
111. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree?
112. Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells
113. Adenosine 3':5'-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells
114. Cell biology of von Willebrand factor
115. Von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain
116. Nervous regulation of factor-VIII levels in man
117. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site directed mutagenesis
118. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo
119. Mechanisms of plasminogen activation
120. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels
121. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay
122. Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation
123. Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo
124. Characterization of human platelet beta-adrenoreceptors
125. Effects of stress and beta-blockade on platelet function
126. Epinephrine potentiates human platelet activation but is not an aggregating agent
127. Vasoactive agents and production of thrombosis during intravascular coagulation. 3. Comparative effects of catecholamines
128. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding, and aggregation in whole blood in the absence of other excitatory agonists
129. Expression of fibrinogen receptors during activation and subsequent desensitization of human platelets by epinephrine
130. Sympathetic drive and vascular damage in hypertension and atherosclerosis
131. Von Willebrand factor and cardiovascular disease
132. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severly damaged arterial wall
133. Mechanisms initiating platelet thrombus formation
134. Synergistic effect of epinephrine and shearing on platelet activation
135. Epinephrine and shear stress synergistically induce platelet aggregation via a mechanism that partially bypasses vWF-GP Ib interactions
136. Haemostatic risk factors for cardiovascular diseases
137. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
138. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
139. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
140. The PLAT Study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results
141. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
142. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction
143. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
144. The haemostatic balance - Astrup revisited
145. Factors affecting the coagulation time of blood. IV. The hastening of coagulation in pain and emotional excitement
146. Endothelial cells in physiology and in the pathophysiology of vascular disorders
147. Fibrinolisi e cold-pressor-test
148. Different platelet aggregability during mental stress in two stages of essential hypertension
149. Decreased fibrinolytic response to adrenergic stimulation in hypertensive patients
150. Effect of mental stress on platelet function in normal subjects and in patients with coronary artery disease
151. Antithrombin III biological activity and emotional stress in patients with coronary artery disease
152. Triggering of acute myocardial infarction onset by episodes of anger
153. Plasma catecholamines in stress and exercise
154. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: Relationship to infarct extent and mortality
155. Hemostatic factors as triggers of cardiovascular events
156. Effect of systemic alpha-2 adrenergic blockade on the morning increase in platelet aggregation in normal subjects
157. Fundamental mechanisms involved in thrombosis and haemostasis